APA (7th ed.) Citation

Kelaidi, C., Beyne-Rauzy, O., Braun, T., Sapena, R., Cougoul, P., Adès, L., . . . Cheze, S. (2013). Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Annals of Hematology, 92(5), 633. https://doi.org/10.1007/s00277-013-1713-5

Chicago Style (17th ed.) Citation

Kelaidi, C., et al. "Erratum to: High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa with or Without Filgrastim in Lower-risk Myelodysplastic Syndromes: A Phase II Study by the GFM." Annals of Hematology 92, no. 5 (2013): 633. https://doi.org/10.1007/s00277-013-1713-5.

MLA (9th ed.) Citation

Kelaidi, C., et al. "Erratum to: High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa with or Without Filgrastim in Lower-risk Myelodysplastic Syndromes: A Phase II Study by the GFM." Annals of Hematology, vol. 92, no. 5, 2013, p. 633, https://doi.org/10.1007/s00277-013-1713-5.